**Priority-driven Collaborative Cancer Research Scheme 2023**

Cancer Australia, Australian Lions Childhood Cancer Research Foundation, Bowel Cancer Australia, Can Too Foundation, Cooper Rice-Brading Foundation, Leukaemia Foundation, Lung Foundation Australia, My Room Children’s Cancer Charity Limited, National Breast Cancer Foundation, Neuroblastoma Australia, Ovarian Cancer Research Foundation, and The Kids’ Cancer Project are pleased to announce successful applicants in the 2023 round of the Priority-driven Collaborative Cancer Research Scheme.

**Boyle, Sarah**Centre for Cancer Biology (University of South Australia and SA Pathology)  
*Tackling breast cancer growth and metastasis by suppressing ROCK-regulated paracrine signalling.*Funded by: Cancer Australia, Can Too Foundation

**Byrne, Hilary**University of Sydney  
*How are you breathing today?*Funded by: Cancer Australia, Lung Foundation Australia

**Cole, Alexander**Centenary Institute  
*Treating chemoresistant ovarian cancer: Blocking follistatin signalling to enhance the effects of chemotherapy and prevent recurrence of chemoresistant disease.*Funded by: Cancer Australia, Ovarian Cancer Research Foundation

**D'Andrea, Richard**University of South Australia  
*Integrating cancer germline genetics, precision medicine and oncology to optimise management of paediatric AML.*Funded by: Cancer Australia, My Room Children’s Cancer Charity Limited, The Kids’ Cancer Project

**Dun, Matt**The University of Newcastle  
*Taming free radicals to silence the epigenome of kinase active paediatric cancers.*Funded by: Cancer Australia, The Kids’ Cancer Project

**Hindley, Nicholas**University of Sydney  
*From relativity to respiration: How ideas from Einstein’s general theory enable adaptative* *radiation therapy for lung cancer patients.*Funded by: Cancer Australia, Lung Foundation Australia

**McDonald, Michelle**University of Sydney  
*The Skeleton: A Reservoir for Metastatic Outgrowth.*Funded by: Cancer Australia

**Park, Susanna**University of Sydney  
*Harnessing metabolic, genetic and protein biomarkers to predict neurotoxicity in taxane-treated cancer patients (NeuroTax): A prospective validation cohort study*Funded by: Cancer Australia

**Samuel, Michael**University of South Australia  
*Insights from the functional tumour secretome: new opportunities to monitor and halt colorectal cancer progression.*Funded by: Bowel Cancer Australia

**Sanij, Elaine**St Vincent's Institute of Medical Research  
*Harnessing the nucleolar stress response in cancer therapy.*Funded by: Cancer Australia

**Schumacher, Oliver**Edith Cowan University  
*Exercise as a novel therapeutic approach for sensitising prostate cancer to radiotherapy.*Funded by: Cancer Australia, Can Too Foundation

**Selth, Luke**Flinders University  
*A novel hormonal therapy to treat lethal prostate cancer.*Funded by: Cancer Australia

**Sutherland, Kate**The Walter and Eliza Hall Institute of Medical Research  
*Exploiting cell-of-origin features to improve treatment for KEAP1-mutant lung cancer.*Funded by: Cancer Australia

**Tavakoli Shirazi, Paniz**The Council of the Queensland Institute of Medical Research  
*Effect of co-occurring mutations on therapy response and resistance.*Funded by: Cancer Australia

**Thurgood, Lauren**Flinders University  
*Non-canonical PI3K targeting - novel therapies to exploit the lipid dependency of CLL.*Funded by: Leukaemia Foundation

**Vandyke, Kate**The University of Adelaide  
*Priming the blood-brain barrier to improve drug delivery and treatment outcomes in diffuse midline glioma.*Funded by: Cancer Australia, Australian Lions Childhood Cancer Research Foundation, The Kids’ Cancer Project

**Ziegler, David**University of New South Wales  
*Unlocking the potential of the blood-brain barrier in the fight against paediatric brain gliomas*  
Funded by: Cancer Australia